Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

23,629 total articles

SkyAI Comments on Annual Meeting Results

SkyAI Comments on Annual Meeting Results

SkyAI, Inc. acknowledges significant shareholder concerns reflected in the 2026 Annual Meeting voting results. The Board and management are committed to thoroughly engaging with shareholders and evaluating necessary actions related to capital allocation, corporate governance, strategic direction, and shareholder communications to reduce the company…

Nexentis: MitoCareX Strengthens Its Computational Drug Discovery Capabilities with Appointment of Prof. Dan T. Major to Scientific Advisory Board

Nexentis: MitoCareX Strengthens Its Computational Drug Discovery Capabilities with Appointment of Prof. Dan T. Major to Scientific Advisory Board

Nexentis Technologies Inc. has appointed Professor Dan T. Major to the Scientific Advisory Board of its wholly owned subsidiary, MitoCareX Bio Ltd. Prof. Major, an expert in computational chemistry and in silico drug discovery, will advise MitoCareX as it expands its computational drug discovery capabilities to enhance prioritization of its researc…

Sky Quarry Restarts Nevada's Only Crude Oil Refinery

Sky Quarry Restarts Nevada's Only Crude Oil Refinery

Sky Quarry Inc. announced the restart of its Eagle Springs Refinery in Nevada following approval of an air permit by the Nevada Division of Environmental Protection. The refinery, operated by Sky Quarry's subsidiary Foreland Refining Corporation, has a capacity of approximately 5,000 barrels per day. The company completed $300,000 in upgrades and p…

Immuneering to Present at the ESMO Congress 2026

Immuneering to Present at the ESMO Congress 2026

Immuneering Corporation announced that data from its ongoing Phase 3 MAPKeeper 301 trial evaluating atebimetinib in combination with chemotherapy for first-line treatment of metastatic pancreatic cancer will be presented at the ESMO Congress 2026. The trial investigates a novel Deep Cyclic Inhibitor designed to improve survival by shrinking tumors,…

Kala Bio and Virotek Sign Letter of Intent with U.S. DNA Testing Platform to Resell Virotek's Suite of Genetic Testing Products

Kala Bio and Virotek Sign Letter of Intent with U.S. DNA Testing Platform to Resell Virotek's Suite of Genetic Testing Products

Kala Bio and Virotek have signed a non-binding letter of intent with a U.S. DNA testing platform to resell Virotek's genetic testing products, potentially expanding distribution beyond ophthalmology and creating new commercial channels. The agreement is still subject to finalization of terms and definitive agreements. Kala anticipates this could ge…

Profusa Announces Significant Progress Towards Lumee® Oxygen Platform CE Mark with ISO 13485 Certification Expected in Early October

Profusa Announces Significant Progress Towards Lumee® Oxygen Platform CE Mark with ISO 13485 Certification Expected in Early October

Profusa, Inc. announced progress in its quality management certification under ISO 13485 through GMED, moving closer to obtaining MDR conformity assessment and CE marking for its Lumee Oxygen Platform, a biosensor technology for continuous tissue oxygen monitoring. This milestone reflects enhanced compliance with European medical device regulations…

Build Smarter, More Resilient 48V Power Systems with Energy-Aware Digital Power Monitoring from Microchip

Build Smarter, More Resilient 48V Power Systems with Energy-Aware Digital Power Monitoring from Microchip

Microchip Technology announced new 65V digital power monitor families PAC1761 and PAC1861 designed to support growing 48V power architectures across automotive, AI/data center, networking, and industrial sectors. These devices offer enhanced voltage measurement headroom, transient spike protection, and energy-aware real-time power insights to build…

Auddia Announces Adjournment of Special Meeting of Stockholders

Auddia Announces Adjournment of Special Meeting of Stockholders

Auddia Inc. (NASDAQ: AUUD) has adjourned its Special Meeting of Stockholders to October 7, 2026, to allow additional time for shareholders to vote on the proposed merger with Thramann Holdings. Currently, approximately 88% of votes cast support the merger, but a majority of all outstanding shares must approve the transaction. Upon completion, the c…

Satellos Announces FDA Clearance of IND Application for Forazapadin in Facioscapulohumeral Muscular Dystrophy (FSHD) and a Partnership with FSHD Canada Foundation Providing Non-Dilutive Financing to Support Clinical Development

Satellos Announces FDA Clearance of IND Application for Forazapadin in Facioscapulohumeral Muscular Dystrophy (FSHD) and a Partnership with FSHD Canada Foundation Providing Non-Dilutive Financing to Support Clinical Development

Satellos Bioscience Inc. announced FDA clearance of its IND application to begin a Phase 2 clinical trial for forazapadin, a novel oral small molecule drug candidate aimed at muscle regeneration, targeting facioscapulohumeral muscular dystrophy (FSHD). The company secured up to $5 million in non-dilutive financing from the FSHD Canada Foundation to…

Vistagen Reports Positive Findings Supporting Fasedienol’s Potential in Very Severe Social Anxiety Disorder

Vistagen Reports Positive Findings Supporting Fasedienol’s Potential in Very Severe Social Anxiety Disorder

Vistagen announced positive exploratory findings from two clinical trials indicating that its lead product candidate, fasedienol nasal spray, shows potential efficacy in treating individuals with very severe social anxiety disorder. These findings include statistically significant improvements in anxiety symptoms during public speaking challenges a…

Ligand and AvenCell Therapeutics Enter Financing Agreement to Advance Pipeline of Next-Generation CAR-T Therapies for Up to $47 Million

Ligand and AvenCell Therapeutics Enter Financing Agreement to Advance Pipeline of Next-Generation CAR-T Therapies for Up to $47 Million

Ligand Pharmaceuticals has entered a financing agreement with AvenCell Therapeutics to provide up to $47 million to support clinical development of AvenCell's allogeneic CAR-T therapies targeting acute myeloid leukemia and B-cell malignancies. Ligand will receive royalties on the sales of AvenCell's pipeline assets, with funding released upon achie…

Pasqal Reports First Half 2026 Financial Results

Pasqal Reports First Half 2026 Financial Results

Pasqal Holding SA announced its first half 2026 financial results, highlighting 14% year-over-year revenue growth driven by a 34% increase in QPU-related services. The company advanced its quantum computing platform by scaling to over 1,000 physical qubits and expanding commercial partnerships with major players like NVIDIA, Google, and Saudi Aramc…

Cullinan Therapeutics Highlights Fourth Quarter 2026 Milestones Across Immunology and Oncology T Cell Engager Portfolio

Cullinan Therapeutics Highlights Fourth Quarter 2026 Milestones Across Immunology and Oncology T Cell Engager Portfolio

Cullinan Therapeutics, a clinical-stage biopharmaceutical company, announced key upcoming clinical data presentations in late 2026 for its T cell engager drug candidates targeting autoimmune diseases and cancer. Highlights include upcoming multi-dose regimen data for Velinotamig in SLE, CLN-978 in SLE, RA, and Sjögren’s disease, and updated Phase 1…

Descartes Expands AI Innovation with Agent that Helps Reduce Global Trade Data Research and Analysis Time by Up to 90%

Descartes Expands AI Innovation with Agent that Helps Reduce Global Trade Data Research and Analysis Time by Up to 90%

Descartes Systems Group launched the Descartes Datamyne AI Agent, a cutting-edge conversational AI integrated into its global trade intelligence platform. The AI Agent leverages over 500 million annual shipment records from 230 markets to help logistics, sourcing, sales, and supply chain teams reduce trade data research and analysis time by up to 9…

Ducommun’s CEO Sets the Stage for Continued Success, Unveiling the VISION 2032 Game Plan at Investor Day

Ducommun’s CEO Sets the Stage for Continued Success, Unveiling the VISION 2032 Game Plan at Investor Day

Ducommun Incorporated held its first Investor Day in four years, reporting strong progress against its VISION 2027 strategic plan and unveiling the VISION 2032 roadmap. The company aims to accelerate growth through expanded acquisitions, defense franchise expansion, commercial aerospace recovery, and investment in proprietary engineered products. I…